Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate Update

– NDA submission for etripamil in patients with PSVT currently on track for 3Q23 – Company to host virtual KOL event focused on etripamil for the potential treatment of AFib-RVR on Monday, May 22, 2023 – Topline data from Phase 2 ReVeRA study evaluating etripamil in patients with AFib-RVR

0

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
0

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
0

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
0

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)

Share This Story, Choose Your Platform!

Related Posts

Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation

Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster

First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)